Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study.

Awad, Mark M; Le Bruchec, Yvan; Lu, Brian; Ye, Jason; Miller, Julie Ann; Lizotte, Patrick H; Cavanaugh, Megan E; Rode, Amanda J; Dumitru, Calin Dan; Spira, Alexander

Awad, Mark M; Le Bruchec, Yvan; Lu, Brian; Ye, Jason; Miller, Julie Ann; Lizotte, Patrick H; Cavanaugh, Megan E; Rode, Amanda J; Dumitru, Calin Dan; Spira, Alexander.

Afiliación

Awad MM; Lowe Center for Thoracic Oncology and Dana-Farber Cancer Institute, Boston, MA, United States.
Le Bruchec Y; Bristol Myers Squibb, Princeton, NJ, United States.
Lu B; Bristol Myers Squibb, Princeton, NJ, United States.
Ye J; Acetylon Pharmaceuticals, Inc, Boston, MA, United States.
Miller JA; Bristol Myers Squibb, Princeton, NJ, United States.
Lizotte PH; Dana-Farber Cancer Institute and Belfer Center for Applied Cancer Science, Boston, MA, United States.
Cavanaugh ME; Dana-Farber Cancer Institute and Belfer Center for Applied Cancer Science, Boston, MA, United States.
Rode AJ; Dana-Farber Cancer Institute and Belfer Center for Applied Cancer Science, Boston, MA, United States.
Dumitru CD; Bristol Myers Squibb, Princeton, NJ, United States.
Spira A; Virginia Cancer Specialists (VCS) Research Institute, Fairfax, VA, United States.

Front Oncol ; 12: 889996, 2022.

Article en En | MEDLINE | ID: mdl-35747830

RESUMEN

[This corrects the article DOI: 10.3389/fonc.2021.696512.].

Palabras clave

ACY-241; HDAC6; citarinostat; nivolumab; non-small cell lung cancer

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google